A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Eli Lilly and Company
Cantargia AB
Emory University
Canadian Cancer Trials Group
Cantargia AB
Nektar Therapeutics
Incyte Corporation
Holy Name Medical Center, Inc.
Eli Lilly and Company
Masonic Cancer Center, University of Minnesota
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NYU Langone Health